MoFo Life Sciences

October 13, 2021 - Global, Agtech, Regulatory, Intellectual Property
European Union Adopts Regulation to Extend Term of Community Plant Variety Rights in Europe for Varieties of Certain Plant Species
10/27/2021 Update : The adopted regulation ((EU) 2021/1873) is now officially published in the Journal of the EU. In accordance with the vote of the Council of the European Union on October 5, 2021, the European Union has adopted a new regulation aimed at
... ›
October 08, 2021 - United States, FDA, Litigation, Pharma, Intellectual Property
Skinny Labels Back in Focus after HHS Report on Addressing Drug Prices
By: Fitz B. Collings
Skinny labels are back in focus at the White House. On September 9, 2021, the U.S. Department of Health and Human Services submitted its much-anticipated report to the White House Competition Counsel regarding a “Comprehensive Plan for Addressing High Drug Prices.” The HHS Report—issued
... ›
April 19, 2021 - Litigation, European Union, Pharma, Intellectual Property, Antitrust
Pay-for-Delay has a tough (antitrust) time at EU Top Court
By: Jens Hackl and Andreas Grünwald
In recent years, there have been various antitrust investigations in the pharmaceutical sector resulting in decisions of the European Commission (EC) and the European Courts.[1] In two recent rulings – “Lundbeck”[2] and “Paroxetine”[3] – the European Court of Justice (ECJ) dealt with settlement agreements
... ›
March 02, 2021 - United States, European Union, Intellectual Property
Key EU Intellectual Property and Trade Secrets
By: Wolfgang Schönig and Mark L. Whitaker
Session 11 of the GSAS Harvard Biotech Club and Morrison & Foerster course on Legal Topics for Scientists, Entrepreneurs, and Start Ups was led by Life Sciences Transactions + Licensing partner Wolfgang Schoenig focusing on key EU Intellectual Property. Wolfgang discussed Intellectual Property Rights,
... ›
January 05, 2021 - United States, Litigation, Intellectual Property
Considerations for ANDA and BPCIA Litigation
By: Matthew A. Chivvis and Michael R. Ward
Matthew Chivvis , life sciences IP litigation partner in Morrison & Foerster’s San Francisco office led session 5 of our course on Legal Topics for Scientists, Entrepreneurs, and Start Ups. Matthew discussed the Hatch-Waxman and Biologics Price Competition and Innovation Act for generics and
... ›
December 17, 2020 - COVID-19, Biotech, European Union, Pharma, Data Analytics, Intellectual Property
The European Commission’s New Pharmaceutical Strategy for Europe
By: Wolfgang Schönig
Nina Schäfer and Jin Ito contributed to this article. On November 25, 2020, the European Commission (the “Commission”) published its “ Pharmaceutical Strategy for Europe ” which outlines the Commission’s multi-year vision for a more patient-centered pharmaceutical system. The strategy aims to achieve various
... ›
November 23, 2020 - Licensing + Commercial, FDA, COVID-19, Intellectual Property
Podcast: Toward a Therapy for COVID-19: The Science and Legal Considerations
By: Janet Xiao and Michael R. Ward
Researchers around the world are working at record speed to find the best ways to treat and prevent COVID-19. In this last episode of our four-part podcast series, we discuss the science, regulatory framework, and commercial transaction considerations of a COVID-19 therapy. Michael Ward,
... ›
November 17, 2020 - United States, Corporate + Venture Capital, United Kingdom, Startup, Intellectual Property
GSAS Harvard Biotech Club and Morrison & Foerster’s New Course
By: Andrew Boyd, Alfredo B. D. Silva, Anita Choi and Michael R. Ward
MoFo & GSAS Harvard Biotech Club’s new course, “ Legal Topics for Scientists, Entrepreneurs, and Start Ups ,” started on November 11, with more than 100 life sciences graduate students, post-docs, and industry professionals. The Harvard Biotech Club is a student organization that seeks to
... ›
November 09, 2020 - Licensing + Commercial, United States, Corporate + Venture Capital, FDA, United Kingdom, Litigation, Startup, Regulatory, Intellectual Property, Announcements
Legal Topics for Scientists, Entrepreneurs, and Start Ups
By: Michael R. Ward, Anita Choi, Andrew Boyd, Alfredo B. D. Silva, Matthew Karlyn, Jim Krenn and Matthew A. Chivvis
The GSAS Harvard Biotech Club and Morrison & Foerster course on Legal Topics for Scientists, Entrepreneurs, and Start Ups features a combination of lectures and interactive workshops and is designed for students, post-docs, entrepreneurs, and investors with life sciences and tech backgrounds to learn
... ›
November 03, 2020 - Licensing + Commercial, FDA, COVID-19, Intellectual Property
Podcast: Toward a Vaccine for COVID-19: The Science and Legal Considerations
By: Otis Littlefield and Michael R. Ward
In this third of a four-part podcast series, we discuss the science, regulatory framework, and commercial transactions considerations of a COVID-19 vaccine. Michael Ward, MoFo partner and global head of the firm’s Life Sciences Group and Patent Group, discusses these issues among others with:
... ›

Topic Archives: Intellectual Property

European Union Adopts Regulation to Extend Term of Community Plant Variety Rights in Europe for Varieties of Certain Plant Species

Skinny Labels Back in Focus after HHS Report on Addressing Drug Prices

By: Fitz B. Collings

Pay-for-Delay has a tough (antitrust) time at EU Top Court

By: Jens Hackl and Andreas Grünwald

Key EU Intellectual Property and Trade Secrets

By: Wolfgang Schönig and Mark L. Whitaker

Considerations for ANDA and BPCIA Litigation

By: Matthew A. Chivvis and Michael R. Ward

The European Commission’s New Pharmaceutical Strategy for Europe

By: Wolfgang Schönig

Podcast: Toward a Therapy for COVID-19: The Science and Legal Considerations

By: Janet Xiao and Michael R. Ward

GSAS Harvard Biotech Club and Morrison & Foerster’s New Course

By: Andrew Boyd, Alfredo B. D. Silva, Anita Choi and Michael R. Ward

Legal Topics for Scientists, Entrepreneurs, and Start Ups

By: Michael R. Ward, Anita Choi, Andrew Boyd, Alfredo B. D. Silva, Matthew Karlyn, Jim Krenn and Matthew A. Chivvis

Podcast: Toward a Vaccine for COVID-19: The Science and Legal Considerations

By: Otis Littlefield and Michael R. Ward